AI Engines For more Details: Perplexity Kagi Labs You
Schizophrenia: Pimozide is effective in managing the positive symptoms of schizophrenia, including hallucinations (auditory, visual, or tactile), delusions (false beliefs), disorganized thinking, and agitation. It helps to reduce the severity and frequency of psychotic episodes and improve overall functioning in individuals with schizophrenia.
Delusional Disorders: Pimozide is also used to treat delusional disorders characterized by persistent, non-bizarre delusions (fixed false beliefs) that are not attributable to other psychiatric conditions such as schizophrenia or mood disorders. Pimozide helps to reduce the intensity of delusional symptoms and improve insight into the irrationality of the beliefs.
Tourette Syndrome: Pimozide is sometimes prescribed off-label for the treatment of Tourette syndrome, a neurological disorder characterized by repetitive, involuntary movements and vocalizations called tics. Pimozide may help to reduce the frequency and severity of tics, although its use in Tourette syndrome is less common than other medications such as antipsychotics or alpha-2 adrenergic agonists.
Antipsychotic Action: Pimozide exerts its therapeutic effects by blocking dopamine D2 receptors in the brain. By inhibiting dopamine transmission, pimozide helps to reduce the hyperactivity of dopamine pathways implicated in psychotic symptoms. This dopamine-blocking action is thought to underlie its antipsychotic properties.
Maintenance Therapy: Pimozide may be used for long-term maintenance therapy in individuals with chronic psychotic disorders to prevent relapse and stabilize symptoms over time. Regular monitoring by a healthcare professional is necessary to assess treatment response, manage side effects, and adjust dosage as needed.
Side Effects: Pimozide can cause a range of side effects, including extrapyramidal symptoms (such as tremors, rigidity, and dystonia), sedation, weight gain, dry mouth, constipation, blurred vision, and sexual dysfunction. In some cases, pimozide may also prolong the QT interval on electrocardiogram (ECG), increasing the risk of cardiac arrhythmias, particularly torsades de pointes.
Monitoring: Due to its potential for adverse effects, including cardiac effects, individuals taking pimozide require regular monitoring of vital signs, ECG, and blood tests to assess cardiac function and metabolic parameters. Close supervision by a healthcare provider is essential throughout treatment with pimozide.
Contraindications: Pimozide is contraindicated in individuals with a history of QT prolongation, cardiac arrhythmias, severe cardiovascular disease, or hypersensitivity to the medication. It should not be used concomitantly with certain medications that may interact with pimozide or prolong the QT interval.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Akkermansia muciniphila | Reduces |
| species | Bacteroides uniformis | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Escherichia coli | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
| species | Parabacteroides distasonis | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.6 | 0.6 | |
| Acne | 0.3 | 0.5 | -0.67 |
| ADHD | 3.7 | 0.6 | 5.17 |
| Age-Related Macular Degeneration and Glaucoma | 1.1 | 0.4 | 1.75 |
| Allergic Rhinitis (Hay Fever) | 3.4 | 2.3 | 0.48 |
| Allergies | 5.6 | 2.3 | 1.43 |
| Allergy to milk products | 1.5 | 1.6 | -0.07 |
| Alopecia (Hair Loss) | 1.6 | 1.6 | |
| Alzheimer's disease | 5.1 | 6.1 | -0.2 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 2.6 | 0.7 | 2.71 |
| Ankylosing spondylitis | 4.9 | 1.5 | 2.27 |
| Anorexia Nervosa | 1.3 | 2.9 | -1.23 |
| Antiphospholipid syndrome (APS) | 2.1 | 2.1 | |
| Asthma | 6.2 | 2 | 2.1 |
| Atherosclerosis | 2.3 | 2.1 | 0.1 |
| Atrial fibrillation | 3.5 | 2.8 | 0.25 |
| Autism | 9.3 | 8.7 | 0.07 |
| Autoimmune Disease | 1.2 | 1 | 0.2 |
| Barrett esophagus cancer | 0.6 | 0.3 | 1 |
| benign prostatic hyperplasia | 0.6 | 0.3 | 1 |
| Biofilm | 2.7 | 2.7 | |
| Bipolar Disorder | 1.8 | 1.1 | 0.64 |
| Brain Trauma | 0.9 | 1.1 | -0.22 |
| Breast Cancer | 0.9 | 0.9 | |
| Cancer (General) | 0.9 | 1.5 | -0.67 |
| Carcinoma | 4.1 | 2.3 | 0.78 |
| Celiac Disease | 3.5 | 2.9 | 0.21 |
| Cerebral Palsy | 1.4 | 1 | 0.4 |
| Chronic Fatigue Syndrome | 4.5 | 4.5 | 0 |
| Chronic Kidney Disease | 4.2 | 2 | 1.1 |
| Chronic Lyme | 0.6 | 0.8 | -0.33 |
| Chronic Obstructive Pulmonary Disease (COPD) | 2.8 | 1.7 | 0.65 |
| Chronic Urticaria (Hives) | 1.9 | 1.3 | 0.46 |
| Coagulation / Micro clot triggering bacteria | 1.9 | 1 | 0.9 |
| Cognitive Function | 2.8 | 1.6 | 0.75 |
| Colorectal Cancer | 8.5 | 2.8 | 2.04 |
| Constipation | 1.8 | 0.7 | 1.57 |
| Coronary artery disease | 2.6 | 2.7 | -0.04 |
| COVID-19 | 8.3 | 9.1 | -0.1 |
| Crohn's Disease | 8.8 | 4.9 | 0.8 |
| Cushing's Syndrome (hypercortisolism) | 0.9 | -0.9 | |
| cystic fibrosis | 1.2 | 1.4 | -0.17 |
| d-lactic acidosis (one form of brain fog) | 0.6 | 0.6 | |
| deep vein thrombosis | 2.8 | 1.1 | 1.55 |
| Denture Wearers Oral Shifts | 1.6 | 1.6 | |
| Depression | 10.4 | 8.2 | 0.27 |
| Dermatomyositis | 0.3 | 0.3 | 0 |
| Eczema | 2.3 | 2.2 | 0.05 |
| Endometriosis | 3.2 | 2 | 0.6 |
| Eosinophilic Esophagitis | 0.3 | 0.6 | -1 |
| Epilepsy | 3.9 | 1.9 | 1.05 |
| erectile dysfunction | 2.4 | 0.3 | 7 |
| Fibromyalgia | 3.5 | 2 | 0.75 |
| Functional constipation / chronic idiopathic constipation | 5.3 | 3.3 | 0.61 |
| gallstone disease (gsd) | 4 | 1.2 | 2.33 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 2.1 | 0.6 | 2.5 |
| Generalized anxiety disorder | 3.1 | 1.9 | 0.63 |
| giant cell arteritis | 0.2 | -0.2 | |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 0.7 | 0.3 | 1.33 |
| Graves' disease | 1.6 | 2.7 | -0.69 |
| Gulf War Syndrome | 0.6 | 1.7 | -1.83 |
| Halitosis | 1.5 | 0.3 | 4 |
| Hashimoto's thyroiditis | 3.3 | 1.2 | 1.75 |
| Heart Failure | 4 | 1.6 | 1.5 |
| hemorrhagic stroke | 1.3 | 1.3 | |
| Hidradenitis Suppurativa | 1.2 | 0.3 | 3 |
| High Histamine/low DAO | 1.8 | 0.3 | 5 |
| hypercholesterolemia (High Cholesterol) | 1.1 | 0.1 | 10 |
| hyperglycemia | 2.8 | 1.3 | 1.15 |
| Hyperlipidemia (High Blood Fats) | 0.6 | 0.3 | 1 |
| hypersomnia | 0.4 | -0.4 | |
| hypertension (High Blood Pressure | 4.2 | 4.1 | 0.02 |
| Hypothyroidism | 0.1 | 0.7 | -6 |
| Hypoxia | 3.5 | 0.9 | 2.89 |
| IgA nephropathy (IgAN) | 1.6 | 4.1 | -1.56 |
| Inflammatory Bowel Disease | 10.1 | 7.4 | 0.36 |
| Insomnia | 2.3 | 2.3 | 0 |
| Intelligence | 1.7 | 0.6 | 1.83 |
| Intracranial aneurysms | 1.1 | 0.6 | 0.83 |
| Irritable Bowel Syndrome | 6.7 | 4.3 | 0.56 |
| ischemic stroke | 2.6 | 1.7 | 0.53 |
| Liver Cirrhosis | 7.6 | 4.1 | 0.85 |
| Long COVID | 6.3 | 4.9 | 0.29 |
| Low bone mineral density | 0.8 | -0.8 | |
| Lung Cancer | 0.6 | 0.8 | -0.33 |
| Lymphoma | 0.6 | 0.6 | |
| Mast Cell Issues / mastitis | 1.2 | 0.3 | 3 |
| ME/CFS with IBS | 0.5 | 0.9 | -0.8 |
| ME/CFS without IBS | 2 | 2 | 0 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 0.7 | 0.6 | 0.17 |
| Metabolic Syndrome | 6.4 | 7 | -0.09 |
| Mood Disorders | 9.5 | 6.1 | 0.56 |
| multiple chemical sensitivity [MCS] | 1.3 | 0.1 | 12 |
| Multiple Sclerosis | 6.6 | 5.4 | 0.22 |
| Multiple system atrophy (MSA) | 1.5 | 0.4 | 2.75 |
| myasthenia gravis | 0.9 | 0.7 | 0.29 |
| neuropathic pain | 0.3 | 2.6 | -7.67 |
| Neuropathy (all types) | 0.8 | 1.6 | -1 |
| neuropsychiatric disorders (PANDAS, PANS) | 1.1 | 1.1 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 5.4 | 3.1 | 0.74 |
| NonCeliac Gluten Sensitivity | 1.4 | 0.6 | 1.33 |
| Obesity | 8.6 | 8.1 | 0.06 |
| obsessive-compulsive disorder | 5.2 | 3.7 | 0.41 |
| Osteoarthritis | 3.1 | 0.9 | 2.44 |
| Osteoporosis | 2.2 | 1.4 | 0.57 |
| pancreatic cancer | 0.9 | 0.3 | 2 |
| Parkinson's Disease | 7.1 | 7.5 | -0.06 |
| Polycystic ovary syndrome | 6.1 | 2.1 | 1.9 |
| Postural orthostatic tachycardia syndrome | 0.2 | 0.3 | -0.5 |
| Premenstrual dysphoric disorder | 0.7 | 0.4 | 0.75 |
| primary biliary cholangitis | 1.2 | 1.7 | -0.42 |
| Primary sclerosing cholangitis | 2.8 | 2 | 0.4 |
| Psoriasis | 2.7 | 3.2 | -0.19 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 6.2 | 4.4 | 0.41 |
| Rosacea | 0.5 | 1 | -1 |
| Schizophrenia | 5.3 | 2.5 | 1.12 |
| scoliosis | 0.6 | 0.1 | 5 |
| Sjögren syndrome | 2.9 | 2.7 | 0.07 |
| Sleep Apnea | 1.6 | 1.3 | 0.23 |
| Slow gastric motility / Gastroparesis | 1.1 | 0.3 | 2.67 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1.9 | 0.3 | 5.33 |
| Stress / posttraumatic stress disorder | 3.3 | 2.6 | 0.27 |
| Systemic Lupus Erythematosus | 4.3 | 2.1 | 1.05 |
| Tic Disorder | 1.2 | 1.8 | -0.5 |
| Tourette syndrome | 0.9 | 0.3 | 2 |
| Type 1 Diabetes | 3.2 | 3.3 | -0.03 |
| Type 2 Diabetes | 7.4 | 7 | 0.06 |
| Ulcerative colitis | 6.4 | 6.5 | -0.02 |
| Unhealthy Ageing | 5 | 2.2 | 1.27 |
| Vitiligo | 2.2 | 1 | 1.2 |
